Where can I get compounded semaglutide near me in 2026?

Availability has dramatically narrowed. Major telehealth platforms (Hims, Sequence) exited compounded GLP-1 in early 2026. Some independent 503A retail compounding pharmacies still produce semaglutide for individual prescriptions in some states (more in TX/FL/AZ than in CA/NY/IL). The FDA proposed permanently ending mass compounding April 30, 2026. Don't build a long-term plan around compounded supply.

Is compounded semaglutide legal in 2026?

In a narrowing legal grey zone. 503B mass compounding is proposed to end permanently (FDA April 30, 2026 proposal, public comment closes June 29, 2026). Individual 503A retail compounding for documented medical need may continue. Compounded semaglutide bought from foreign mail-order pharmacies or 'no prescription' sites is illegal and dangerous.

Why did Hims stop selling compounded semaglutide?

Hims exited February 7, 2026 amid Novo Nordisk lawsuit pressure and FDA enforcement signaling. Most major telehealth platforms followed. The combination of (a) shortage officially resolved by Novo, (b) FDA escalating enforcement, and (c) brand lawsuit risk made compounded GLP-1 too risky for publicly-traded telehealth companies to continue.

What's the cheapest legitimate alternative to compounded semaglutide?

Orforglipron via LillyDirect at $149/month is now the cheapest legitimate path. Cheaper than most compounded semaglutide pricing was. FDA-approved April 2026 for weight management. Daily oral pill, no fasting requirement. Different molecule (orforglipron is non-peptide; semaglutide is peptide) but comparable weight-loss efficacy in trials.

Will compounded semaglutide come back if the FDA rule doesn't pass?

Possibly, but expect ongoing regulatory pressure even if the specific April 2026 rule doesn't finalize. Novo Nordisk's lawsuits against compounders continue. The legal grey zone narrows incrementally regardless of any single FDA decision. Don't build a treatment plan assuming compounded will remain widely available long-term.

Weight LossJune 2, 2026· Medically reviewed

Compounded semaglutide near me in 2026: where it's actually still available

4 min readUpdated June 2026

Apr 0 2026: FDA proposed permanent end of 503B compounding
Jun 0 2026: FDA comment period close
Feb 06: Hims exited compounded GLP-1 market
0+: FDA warning letters in 2026

Jump to section

What's actually happening to compounded semaglutide in 2026

The 2022-2024 FDA semaglutide shortage allowed 503B outsourcing facilities and 503A retail compounders to produce semaglutide at scale. Telehealth platforms — Hims, Sequence, Push Health, dozens of independents — sold compounded semaglutide at $150-400/month, substantially cheaper than branded Wegovy.

That era is rapidly ending. Novo Nordisk declared the shortage resolved in late 2024. The FDA confirmed resolution a on April 30, 2026 proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B bulk-compounding list. Public comment closes June 29, 2026.

Hims and Hers exited the compounded GLP-1 market on February 7, 2026 amid regulatory pressure and a Novo Nordisk lawsuit. Sequence (Weight Watchers) and most major telehealth platforms followed.

Net result: compounded semaglutide is in active wind-down. State-by-state availability varies significantly.

State-by-state availability (general patterns)

California, New York, Illinois: state pharmacy boards actively enforcing FDA April 2026 guidance. Compounding pharmacies under significant pressure. Most large compounders have exited semaglutide; smaller 503A pharmacies may still compound on individual prescriptions for documented medical need only.

Texas, Florida, Georgia, Arizona: more permissive enforcement timeline. Some 503A retail compounding still occurring through independent pharmacies. Not the same scale as 2023-2024.

Massachusetts, Washington, Oregon: relatively strict enforcement environment. Compounded semaglutide largely unavailable through retail channels.

Generally: rural and southern states have somewhat more availability than coastal urban states. But this is changing rapidly — what's available in June 2026 may be gone by September 2026.

How to actually find compounded semaglutide (if pursuing this path)

Independent pharmacies that compound. Major chain pharmacies (CVS, Walgreens, Rite Aid) do not compound. You need a 503A retail compounding pharmacy. Use the PCAB (Pharmacy Compounding Accreditation Board) directory or search for 'compounding pharmacy near me.'

Telehealth platforms still in the market. Most major platforms have exited. A few independent telehealth services still prescribe compounded semaglutide as of mid-2026 — but legitimacy varies widely. Verify the prescribing physician is licensed in your state and the dispensing pharmacy is registered and accredited.

Red flags to avoid: 'No prescription needed' offers, prices below $100/month, foreign-pharmacy mail-order, no physical pharmacy address, no licensed clinician involvement.

Quality concerns: compounded drugs don't undergo FDA review for safety, efficacy, or manufacturing quality. Recent FDA warning letters cite dosing errors, contamination, and mislabeling. Even legitimate compounders vary in quality control.

Legitimate alternatives that will be cheaper than compounded in 6-12 months

Orforglipron via LillyDirect at $149/month. This is now cheaper than most compounded semaglutide pricing. Daily oral pill, FDA-approved April 2026. Different molecule than semaglutide but comparable efficacy. Likely the answer for most patients currently on compounded.

Zepbound vials via LillyDirect at $349-549/month. Same molecule (tirzepatide) as injectable Zepbound pens, but vials are substantially cheaper. Better efficacy than semaglutide (~22% vs ~15% weight loss).

NovoCare Wegovy self-pay at $499/month. Manufacturer direct-pay program for cash patients without insurance coverage. Comparable to compounded pricing but with FDA-approved branded product.

Insurance appeal. Many self-pay patients have insurance that initially denied. About 40-60% of properly appealed denials succeed. Worth attempting before moving to compounded path.

What happens if you're currently on compounded

Don't panic. Compounded supply is winding down but not instantly gone. You have time to plan a transition.

Talk to your prescriber soon. They can document your current dose, response, and medical history to make insurance appeals or brand-name PA easier.

Plan a transition path. Options: switch to orforglipron $149/mo (different molecule, similar efficacy), Zepbound LillyDirect vials $349-549/mo (better efficacy), branded Wegovy through insurance or NovoCare $499/mo.

Don't suddenly stop. Discontinuation without a plan typically causes rapid weight regain (50-70% of lost weight within 12 months on average). Bridge to another GLP-1 option ideally.

What to do if no legitimate path works

Insurance appeal with full documentation. Use our appeal letter generator. Multiple appeal levels available. 40-60% success on properly documented appeals.

Direct request to manufacturer patient assistance program (PAP). NovoCare and LillyDirect PAPs exist for patients with documented inability to pay. Application required.

Discuss orforglipron specifically. $149/mo flat pricing makes it the cheapest legitimate path in 2026 for most patients. Many patients currently on compounded are clinically appropriate for orforglipron.

Lifestyle-only plus monitoring if no medication path is affordable. Not ideal, but maintainable with structured support. Some patients use this temporarily before insurance coverage becomes available.

Sources

Primary sources cited above. FDA labeling, peer-reviewed trials, and specialty-society guidelines only.

FDA Proposal to Remove Semaglutide and Tirzepatide from 503B Bulk-Compounding List · U.S. Food and Drug Administration, 2026
Hims & Hers Exits Compounded GLP-1 Market · Press release / industry coverage, 2026
FDA Warning Letters Issued to Compounding Pharmacies · U.S. Food and Drug Administration, 2026